These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26275018)

  • 1. Crystal Habits of Itraconazole Microcrystals: Unusual Isomorphic Intergrowths Induced via Tuning Recrystallization Conditions.
    Mugheirbi NA; Tajber L
    Mol Pharm; 2015 Sep; 12(9):3468-78. PubMed ID: 26275018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of crystal habit on the dissolution behaviour of simvastatin crystals and its relationship to crystallization solvent properties.
    Bukovec P; Benkic P; Smrkolj M; Vrecer F
    Pharmazie; 2016 May; 71(5):263-8. PubMed ID: 27348970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesophase and size manipulation of itraconazole liquid crystalline nanoparticles produced via quasi nanoemulsion precipitation.
    Mugheirbi NA; Tajber L
    Eur J Pharm Biopharm; 2015 Oct; 96():226-36. PubMed ID: 26264714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heat induced evaporative antisolvent nanoprecipitation (HIEAN) of itraconazole.
    Mugheirbi NA; Paluch KJ; Tajber L
    Int J Pharm; 2014 Aug; 471(1-2):400-11. PubMed ID: 24879938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced dissolution of megestrol acetate microcrystals prepared by antisolvent precipitation process using hydrophilic additives.
    Cho E; Cho W; Cha KH; Park J; Kim MS; Kim JS; Park HJ; Hwang SJ
    Int J Pharm; 2010 Aug; 396(1-2):91-8. PubMed ID: 20558265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microfluidic droplet liquid reactors for active pharmaceutical ingredient crystallization by diffusion controlled solvent extraction.
    Tona RM; McDonald TAO; Akhavein N; Larkin JD; Lai D
    Lab Chip; 2019 Jun; 19(12):2127-2137. PubMed ID: 31114833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supercritical fluid crystallization of griseofulvin: crystal habit modification with a selective growth inhibitor.
    Jarmer DJ; Lengsfeld CS; Anseth KS; Randolph TW
    J Pharm Sci; 2005 Dec; 94(12):2688-702. PubMed ID: 16258994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-step preparation and deagglomeration of itraconazole microflakes by supercritical antisolvent method for dissolution enhancement.
    Sathigari SK; Ober CA; Sanganwar GP; Gupta RB; Babu RJ
    J Pharm Sci; 2011 Jul; 100(7):2952-65. PubMed ID: 21344415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cocrystal habit engineering to improve drug dissolution and alter derived powder properties.
    Serrano DR; O'Connell P; Paluch KJ; Walsh D; Healy AM
    J Pharm Pharmacol; 2016 May; 68(5):665-77. PubMed ID: 26408342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying solubility enhancement due to particle size reduction and crystal habit modification: case study of acetyl salicylic acid.
    Hammond RB; Pencheva K; Roberts KJ; Auffret T
    J Pharm Sci; 2007 Aug; 96(8):1967-73. PubMed ID: 17323349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuning in-meso-crystallized lysozyme polymorphism by lyotropic liquid crystal symmetry.
    Zabara A; Amar-Yuli I; Mezzenga R
    Langmuir; 2011 May; 27(10):6418-25. PubMed ID: 21506575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered growth of organic crystalline films using liquid crystal solvents.
    Wilkinson FS; Norwood RF; McLellan JM; Lawson LR; Patrick DL
    J Am Chem Soc; 2006 Dec; 128(51):16468-9. PubMed ID: 17177373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of salmeterol xinafoate microparticle production by conventional and novel antisolvent crystallization.
    Murnane D; Marriott C; Martin GP
    Eur J Pharm Biopharm; 2008 May; 69(1):94-105. PubMed ID: 17981448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissolution enhancement of Deflazacort using hollow crystals prepared by antisolvent crystallization process.
    Paulino AS; Rauber G; Campos CE; Maurício MH; de Avillez RR; Capobianco G; Cardoso SG; Cuffini SL
    Eur J Pharm Sci; 2013 May; 49(2):294-301. PubMed ID: 23557843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisolvent crystallization of pharmaceutical excipients from aqueous solutions and the use of preferred orientation in phase identification by powder X-ray diffraction.
    Crisp JL; Dann SE; Blatchford CG
    Eur J Pharm Sci; 2011 Apr; 42(5):568-77. PubMed ID: 21382490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro dissolution enhancement of micronized l-nimodipine by antisolvent re-crystallization from its crystal form H.
    Zu Y; Li N; Zhao X; Li Y; Ge Y; Wang W; Wang K; Liu Y
    Int J Pharm; 2014 Apr; 464(1-2):1-9. PubMed ID: 24456674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of the phase behavior of polyethylene glycol 6000-itraconazole solid dispersions using DSC.
    Wang X; Michoel A; Van den Mooter G
    Int J Pharm; 2004 Mar; 272(1-2):181-7. PubMed ID: 15019081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of crystal habits on the surface energy and cohesion of crystalline powders.
    Shah UV; Olusanmi D; Narang AS; Hussain MA; Gamble JF; Tobyn MJ; Heng JY
    Int J Pharm; 2014 Sep; 472(1-2):140-7. PubMed ID: 24928138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal morphology modification by the addition of tailor-made stereocontrolled poly(N-isopropyl acrylamide).
    Munk T; Baldursdottir S; Hietala S; Rades T; Kapp S; Nuopponen M; Kalliomäki K; Tenhu H; Rantanen J
    Mol Pharm; 2012 Jul; 9(7):1932-41. PubMed ID: 22591051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bottom-up production of injectable itraconazole suspensions using membrane technology.
    Anjum F; Viville T; Nandi S; Wessner M; De Witte B; Collas A; Sadowski G
    Int J Pharm; 2024 Apr; 654():123977. PubMed ID: 38458403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.